US Patent 11643450 Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
Patent 11643450 was granted and assigned to University of Maryland, Baltimore on May, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 14 Aug, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Lai-Xi Wang0
Wei Huang0
Edits on 10 May, 2023
Golden AI
Edits made to:
Infobox (+16 properties)
Article (+521 characters)
US Patent 11643450 Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
Article
The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
116434500
Date of Patent
May 9, 2023
0Patent Application Number
170975340
Date Filed
November 13, 2020
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11643450 Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.